Chronic neuropathic pain is often refractory to standard pharmacological treatments. Although growing evidence supports the use of inhaled cannabis for neuropathic pain, the lack of standard inhaled dosing plays a major obstacle in cannabis becoming a “main stream” pharmacological treatment for neuropathic pain. The objective of this study was to explore the pharmacokinetics, safety, tolerability, efficacy, and ease of use of a novel portable thermal-metered-dose inhaler (tMDI) for cannabis in a cohort of eight patients suffering from chronic neuropathic pain and on a stable analgesic regimen including medicinal cannabis. In a single-dose, open-label study, patients inhaled a single 15.1 ± 0.1 mg dose of cannabis using the Syqe Inhaler device. Blood samples for Δ9-tetrahydrocannabinol (THC) and 11-hydroxy-Δ9-THC were taken at baseline and up to 120 minutes. Pain intensity (0–10 VAS), adverse events, and satisfaction score were monitored following the inhalation. A uniform pharmacokinetic profile was exhibited across all participants (Δ9-THC plasma Cmax ± SD was 38 ± 10 ng/mL, Tmax ± SD was 3 ± 1 minutes, AUC0→infinity ± SD was 607 ± 200 ng·min/mL). Higher plasma Cmax increase per mg Δ9-THC administered (12.3 ng/mL/mg THC) and lower interindividual variability of Cmax (25.3%), compared with reported alternative modes of THC delivery, were measured. A significant 45% reduction in pain intensity was noted 20 minutes post inhalation (P = .001), turning back to baseline within 90 minutes. Tolerable, lightheadedness, lasting 15–30 minutes and requiring no intervention, was the only reported adverse event. This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a Δ9-THC pharmacokinetic profile with low interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.

Cited by:

Cys-loop receptors on cannabinoids: All high?

Schmiedhofer P, Vogel FD, Koniuszewski F, Ernst M.Front Physiol. 2022 Nov 9;13:1044575. doi: 10.3389/fphys.2022.1044575. eCollection 2022.PMID: 36439263Free PMC article. 3

The Pharmacogenetics of Cannabis in the Treatment of Chronic Pain.

Poli P, Peruzzi L, Maurizi P, Mencucci A, Scocca A, Carnevale S, Spiga O, Santucci A.Genes (Basel). 2022 Oct 11;13(10):1832. doi: 10.3390/genes13101832.PMID: 36292717Free PMC article. 4

THC degradation does not impair the accuracy of THC doses aerosolized by the metered-dose SyqeAir inhaler: a 24-month stability trial.

Aviram J, Atzmony D, Frenklakh A, Kroll A, Zaks I, Hazekamp A.J Cannabis Res. 2022 Oct 24;4(1):55. doi: 10.1186/s42238-022-00166-5.PMID: 36274184Free PMC article. 5

Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.

Monfort A, Ferreira E, Leclair G, Lodygensky GA.Front Pharmacol. 2022 Jul 12;13:919630. doi: 10.3389/fphar.2022.919630. eCollection 2022.PMID: 35903331Free PMC article.Review. 6

Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option?

Zieglgänsberger W, Brenneisen R, Berthele A, Wotjak CT, Bandelow B, Tölle TR, Lutz B.Med Cannabis Cannabinoids. 2022 Mar 22;5(1):61-75. doi: 10.1159/000522432. eCollection 2022.PMID: 35702403Free PMC article.Review. 7

Long-term effectiveness and safety of medical cannabis administered through the metered-dose Syqe Inhaler.

Aviram J, Atzmony D, Eisenberg E.Pain Rep. 2022 May 17;7(3):e1011. doi: 10.1097/PR9.0000000000001011. eCollection 2022 May-Jun.PMID: 35620248Free PMC article. 8

Medicinal Cannabis and Central Nervous System Disorders.

Ortiz YT, McMahon LR, Wilkerson JL.Front Pharmacol. 2022 Apr 21;13:881810. doi: 10.3389/fphar.2022.881810. eCollection 2022.PMID: 35529444Free PMC article.Review. 9

The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids.

Sexton M, Garcia JM, Jatoi A, Clark CS, Wallace MS.J Natl Cancer Inst Monogr. 2021 Nov 28;2021(58):86-98. doi: 10.1093/jncimonographs/lgab011.PMID: 34850897Free PMC article. 10

Safety of Medical Cannabis in Neuropathic Chronic Pain Management.

Bennici A, Mannucci C, Calapai F, Cardia L, Ammendolia I, Gangemi S, Calapai G, Griscti Soler D.Molecules. 2021 Oct 16;26(20):6257. doi: 10.3390/molecules26206257.PMID: 34684842Free PMC article.Review.

Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence.

Verma R, Hoda F, Arshad M, Iqubal A, Siddiqui AN, Khan MA, Haque SE, Akhtar M, Najmi AK.Med Cannabis Cannabinoids. 2021 May 21;4(1):43-60. doi: 10.1159/000515042. eCollection 2021 Jun.PMID: 34676349Free PMC article.Review. 12

Development of a Vaping Machine for the Sampling of THC and CBD Aerosols Generated by Two Portable Dry Herb Cannabis Vaporisers.

Carrara L, Giroud C, Concha-Lozano N.Med Cannabis Cannabinoids. 2020 Jan 14;3(1):84-93. doi: 10.1159/000505027. eCollection 2020 Aug.PMID: 34676343Free PMC article. 13

The Effects of Food on Cannabidiol Bioaccessibility.

Mozaffari K, Willette S, Lucker BF, Kovar SE, Holguin FO, Guzman I.Molecules. 2021 Jun 11;26(12):3573. doi: 10.3390/molecules26123573.PMID: 34208082Free PMC article. 14

Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies.

Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC.Pain. 2021 Jul 1;162(Suppl 1):S5-S25. doi: 10.1097/j.pain.0000000000002268.PMID: 33729211Free PMC article. 15

Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions.

Vázquez M, García-Carnelli C, Maldonado C, Fagiolino P.Adv Exp Med Biol. 2021;1297:27-42. doi: 10.1007/978-3-030-61663-2_3.PMID: 33537935 16

Smokeless consumption of medical cannabis pharmacokinetics, safety and feasibility of the CannaHALER© a phase 1a study.

Ben-Ishay O, Bar-On O, Kluger Y.J Cannabis Res. 2020 Mar 26;2(1):15. doi: 10.1186/s42238-020-00022-4.PMID: 33526119Free PMC article. 17

Cannabis Use and Low-Back Pain: A Systematic Review.

First L, Douglas W, Habibi B, Singh JR, Sein MT.Cannabis Cannabinoid Res. 2020 Dec 15;5(4):283-289. doi: 10.1089/can.2019.0077. eCollection 2020.PMID: 33381642Free PMC article.Review. 18

The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial.

Almog S, Aharon-Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, Hayon Y, Eisenberg E.Eur J Pain. 2020 Sep;24(8):1505-1516. doi: 10.1002/ejp.1605. Epub 2020 Jun 12.PMID: 32445190Free PMC article.Clinical Trial. 19

Medical cannabis for chronic pain: can it make a difference in pain management?

Maharajan MK, Yong YJ, Yip HY, Woon SS, Yeap KM, Yap KY, Yip SC, Yap KX.J Anesth. 2020 Feb;34(1):95-103. doi: 10.1007/s00540-019-02680-y. Epub 2019 Sep 18.PMID: 31535218Review. 20

Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis.

Bellnier T, Brown GW, Ortega TR.Ment Health Clin. 2018 Apr 26;8(3):110-115. doi: 10.9740/mhc.2018.05.110. eCollection 2018 May.PMID: 29955555Free PMC article.

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.

Mouhamed Y, Vishnyakov A, Qorri B, Sambi M, Frank SS, Nowierski C, Lamba A, Bhatti U, Szewczuk MR.Drug Healthc Patient Saf. 2018 Jun 11;10:45-66. doi: 10.2147/DHPS.S158592. eCollection 2018.PMID: 29928146Free PMC article.Review. 22

Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.

Baron EP, Lucas P, Eades J, Hogue O.J Headache Pain. 2018 May 24;19(1):37. doi: 10.1186/s10194-018-0862-2.PMID: 29797104Free PMC article. 23

Cannabis-Associated Asthma and Allergies.

Chatkin JM, Zani-Silva L, Ferreira I, Zamel N.Clin Rev Allergy Immunol. 2019 Apr;56(2):196-206. doi: 10.1007/s12016-017-8644-1.PMID: 28921405Review. 24

Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.

Yuill MB, Hale DE, Guindon J, Morgan DJ.Mol Pain. 2017 Jan-Dec;13:1744806917728227. doi: 10.1177/1744806917728227.PMID: 28879802Free PMC article. 25

A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy.

Sexton M, Cuttler C, Finnell JS, Mischley LK.Cannabis Cannabinoid Res. 2016 Jun 1;1(1):131-138. doi: 10.1089/can.2016.0007. eCollection 2016.PMID: 28861489Free PMC article. 26

Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function.

Gruber SA, Sagar KA, Dahlgren MK, Racine MT, Smith RT, Lukas SE.Front Pharmacol. 2016 Oct 13;7:355. doi: 10.3389/fphar.2016.00355. eCollection 2016.PMID: 27790138Free PMC article. 27

Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues.

Russo EB.Front Pharmacol. 2016 Sep 14;7:309. doi: 10.3389/fphar.2016.00309. eCollection 2016.PMID: 27683558Free PMC article.Review. 28

Safety and Toxicology of Cannabinoids.

Sachs J, McGlade E, Yurgelun-Todd D.Neurotherapeutics. 2015 Oct;12(4):735-46. doi: 10.1007/s13311-015-0380-8.PMID: 26269228Free PMC article.Review. 29

Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations.

Arout CA, Edens E, Petrakis IL, Sofuoglu M.CNS Drugs. 2015 Jun;29(6):465-86. doi: 10.1007/s40263-015-0255-x.PMID: 26142224Review.